search
Back to results

Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation

Primary Purpose

Diarrhea

Status
Completed
Phase
Not Applicable
Locations
Lao People's Democratic Republic
Study Type
Interventional
Intervention
MNP
preventive zinc supplement
therapeutic zinc supplement
preventive placebo supplement
therapeutic placebo supplement
placebo powder
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Diarrhea focused on measuring growth, plasma zinc concentration

Eligibility Criteria

6 Months - 23 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Signed informed consent from at least one parent or primary caregiver
  • Age 6-23 months initially
  • Permanent resident of study area
  • Planned availability during the period of the study
  • Acceptance of home visitors

Exclusion Criteria:

  • Weight-for-height z-score (WHZ) <-3Z with respect to WHO 2006 standards
  • Presence of bipedal edema
  • Severe illness warranting hospital referral
  • Congenital abnormalities potentially interfering with growth
  • Chronic medical condition (e.g. malignancy) requiring frequent medical attention
  • Known HIV infection of index child or child's mother
  • Hemoglobin <70 g/L
  • Currently consuming zinc supplements
  • Current participation in any other clinical trial

Sites / Locations

  • Lao Tropical and Public Health Institute

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

micronutrient powder (MNP)

placebo powder

preventive zinc supplements

therapeutic zinc supplements

Arm Description

preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea

placebo powder plus ORS and therapeutic placebo supplements for diarrhea

preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea

preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea

Outcomes

Primary Outcome Measures

Change in length and length-for-age Z-score
Change in weight and weight-for-age Z-score
Incidence of diarrhea
Change in hemoglobin concentration
Change in micronutrient status
plasma zinc, ferritin, transferrin receptor; and retinol binding protein (RBP) concentrations, measured in a subsample of 560 participants, and controlling for the presence of elevated acute phase protein
Innate and adaptive immune defense
production of cytokines by cultures of peripheral blood white blood cells; and change in concentrations of naïve and memory CD4 and CD8 T-cells and regulatory (Treg) T-cells in a sub-set of 500 children

Secondary Outcome Measures

Change in mid-upper circumference
Achievement of gross motor developmental milestones
Gross motor developmental milestones as recommended by the World Health Organization include: sitting without support, crawling, standing with assistance, walking with assistance, standing alone, walking alone
Change in stool calprotectin concentration
Change in stool neopterin concentration
Change in hair cortisol concentration
Intestinal protozoa parasite infection
Intestinal protozoan infections will be assessed by a modified formalin-ethyl acetate concentration technique
Helminths parasite infection
Helminth parasite infections will be assessed using duplicate Kato-Katz thick smears
Acute and chronic sleep pattern
Assessed by Brief Infant Child Sleep Questionnaire
B-vitamin status
erythrocyte thiamine diphosphate, plasma folate and B12 concentrations and erythrocyte glutathione reductase activation coefficient (EGRac) measured in a randomly selected sub-sample of 260 children (MNP and control group only)

Full Information

First Posted
February 9, 2015
Last Updated
January 4, 2022
Sponsor
University of California, Davis
Collaborators
Lao Tropical and Public Health Institute, Lao PDR, USDA, Western Human Nutrition Research Center, University of British Columbia, Khon Kaen University, Nutrition International, The Mathile Institute for the Advancement of Human Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT02428647
Brief Title
Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation
Official Title
Lao Zinc Study: The Effects of Two Forms of Daily Preventive Zinc Supplementation Versus Therapeutic Zinc Supplementation for Diarrhea on Young Children's Physical Growth and Risk of New Episodes of Diarrhea
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
May 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis
Collaborators
Lao Tropical and Public Health Institute, Lao PDR, USDA, Western Human Nutrition Research Center, University of British Columbia, Khon Kaen University, Nutrition International, The Mathile Institute for the Advancement of Human Nutrition

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will be conducted as a community-based, randomized, placebo-controlled, trial with four study groups. The overall objective of the study is to determine the optimal method for delivering zinc to young children, both for the prevention of zinc deficiency and treatment of diarrhea. In particular, the investigators plan to compare the impact on physical growth, morbidity, micronutrient status, immune function, environmental enteric dysfunction, parasite burden and hair cortisol concentration of: 1) daily preventive zinc supplementation as a micronutrient powder (MNP); 2) placebo powders; 3) daily preventive zinc supplementation as dispersible tablets; 4) therapeutic zinc supplementation as dispersible tablets given in relation to episodes of diarrhea. In addition to the major outcomes mentioned above, the investigators will monitor adherence to the interventions, neuro-behavioral development, and the occurrence of any adverse events.
Detailed Description
Zinc is an essential nutrient that is required for children's normal growth and resistance to infections, including diarrhea and pneumonia, two major causes of child mortality. Current strategies for controlling the growth and infection-related complications of zinc deficiency include: 1) daily or weekly preventive zinc supplementation, and 2) therapeutic zinc supplementation for 10-14 days in relation to episodes of diarrhea. Information is needed on the relative impact of these intervention strategies on children's growth and risk of new episodes of diarrhea (and other infections). Preventive zinc supplements can be delivered either as a single nutrient (zinc) supplement or as a multiple micronutrient (MMN) supplement, such as micronutrient powders (MNP) added to young children's complementary food. Available research indicates that zinc delivered in MNP at the currently recommended dose (4.1-5 mg/d) has not had a measurable impact on zinc-related functional outcomes, like growth and prevention of infection. Moreover, some studies of MMN supplements have detected a greater incidence of diarrhea in the MMN group than in the non-intervention or placebo control groups. Thus, despite the beneficial effects of MNP on prevention of anemia and enhancing iron status, questions have been raised about the desirability of providing zinc in MNP (containing iron and other nutrients) versus a single nutrient formulation offered between meals. For these reasons, the present study is designed to compare both the zinc delivery plan (i.e., preventive versus therapeutic supplementation) as well as the form of delivering zinc (i.e., as a dispersible tablet given between meals or as a MNP given with meals) and to permit assessment of any adverse effects of MNP on the incidence of diarrhea. The study will be conducted as a community-based, randomized, placebo-controlled trial with four study groups in rural communities of Khammouane Province in Central Lao PDR. The project team will enroll a total of ~3,400 children whose ages will range from 6-23 months. Children will be randomly assigned to one of four study group: 1) preventive zinc supplementation provided as LI-MNP plus ORS and placebo tablets for treatment of diarrhea; 2) placebo preventive supplementation provided as placebo powder plus ORS and placebo tablets for diarrhea ; 3) preventive zinc supplementation provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and placebo tablets for diarrhea; and 4) therapeutic zinc supplementation provided as dispersible tablets (containing 20 mg zinc) for diarrhea plus ORS and placebo preventive tablets. The major outcomes that will be monitored include adherence to the interventions; physical growth; incidence, duration and severity of episodes of diarrhea; changes in MN status; immune function; environmental enteric dysfunction; parasite burden; hair cortisol concentration; neuro-behavioral development; and the occurrence of any adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea
Keywords
growth, plasma zinc concentration

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
3433 (Actual)

8. Arms, Groups, and Interventions

Arm Title
micronutrient powder (MNP)
Arm Type
Active Comparator
Arm Description
preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
Arm Title
placebo powder
Arm Type
Placebo Comparator
Arm Description
placebo powder plus ORS and therapeutic placebo supplements for diarrhea
Arm Title
preventive zinc supplements
Arm Type
Active Comparator
Arm Description
preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
Arm Title
therapeutic zinc supplements
Arm Type
Active Comparator
Arm Description
preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
Intervention Type
Dietary Supplement
Intervention Name(s)
MNP
Intervention Description
MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
Intervention Type
Dietary Supplement
Intervention Name(s)
preventive zinc supplement
Intervention Description
7 mg zinc daily as dispersible tablet
Intervention Type
Dietary Supplement
Intervention Name(s)
therapeutic zinc supplement
Intervention Description
20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
Intervention Type
Dietary Supplement
Intervention Name(s)
preventive placebo supplement
Intervention Description
dispersible daily placebo tablet
Intervention Type
Dietary Supplement
Intervention Name(s)
therapeutic placebo supplement
Intervention Description
dispersible placebo tablet for 10 days during diarrhea episodes
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo powder
Intervention Description
placebo powder
Primary Outcome Measure Information:
Title
Change in length and length-for-age Z-score
Time Frame
36 weeks
Title
Change in weight and weight-for-age Z-score
Time Frame
36 weeks
Title
Incidence of diarrhea
Time Frame
36 weeks
Title
Change in hemoglobin concentration
Time Frame
32 weeks
Title
Change in micronutrient status
Description
plasma zinc, ferritin, transferrin receptor; and retinol binding protein (RBP) concentrations, measured in a subsample of 560 participants, and controlling for the presence of elevated acute phase protein
Time Frame
32 weeks
Title
Innate and adaptive immune defense
Description
production of cytokines by cultures of peripheral blood white blood cells; and change in concentrations of naïve and memory CD4 and CD8 T-cells and regulatory (Treg) T-cells in a sub-set of 500 children
Time Frame
32 weeks
Secondary Outcome Measure Information:
Title
Change in mid-upper circumference
Time Frame
36 weeks
Title
Achievement of gross motor developmental milestones
Description
Gross motor developmental milestones as recommended by the World Health Organization include: sitting without support, crawling, standing with assistance, walking with assistance, standing alone, walking alone
Time Frame
after 4, 8, 12, 16, 20, 24, 32 and 36 weeks
Title
Change in stool calprotectin concentration
Time Frame
36 weeks
Title
Change in stool neopterin concentration
Time Frame
36 weeks
Title
Change in hair cortisol concentration
Time Frame
36 weeks
Title
Intestinal protozoa parasite infection
Description
Intestinal protozoan infections will be assessed by a modified formalin-ethyl acetate concentration technique
Time Frame
36 weeks
Title
Helminths parasite infection
Description
Helminth parasite infections will be assessed using duplicate Kato-Katz thick smears
Time Frame
36 weeks
Title
Acute and chronic sleep pattern
Description
Assessed by Brief Infant Child Sleep Questionnaire
Time Frame
after 4, 8, 12, 16, 20, 24, 32 and 36 weeks
Title
B-vitamin status
Description
erythrocyte thiamine diphosphate, plasma folate and B12 concentrations and erythrocyte glutathione reductase activation coefficient (EGRac) measured in a randomly selected sub-sample of 260 children (MNP and control group only)
Time Frame
36 weeks
Other Pre-specified Outcome Measures:
Title
Incidence of serious adverse events
Description
Serious adverse events, including death and required overnight stay in a health facility
Time Frame
36 weeks
Title
Incidence of any non-serious adverse events
Description
non-serious adverse events that may be detected retrospectively, such as the incidence of diarrhea, vomiting, etc., based on the results of morbidity surveillance
Time Frame
36 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
23 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed informed consent from at least one parent or primary caregiver Age 6-23 months initially Permanent resident of study area Planned availability during the period of the study Acceptance of home visitors Exclusion Criteria: Weight-for-height z-score (WHZ) <-3Z with respect to WHO 2006 standards Presence of bipedal edema Severe illness warranting hospital referral Congenital abnormalities potentially interfering with growth Chronic medical condition (e.g. malignancy) requiring frequent medical attention Known HIV infection of index child or child's mother Hemoglobin <70 g/L Currently consuming zinc supplements Current participation in any other clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sonja Y Hess, PhD
Organizational Affiliation
University of California, Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lao Tropical and Public Health Institute
City
Vientiane
Country
Lao People's Democratic Republic

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The complete de-identified dataset will be made publicly available within 3 years after completion of data collection. Associated data dictionaries will be made available along with the datasets.
IPD Sharing Time Frame
Summer 2020
IPD Sharing Access Criteria
Publicly available
IPD Sharing URL
https://osf.io/5bq9c/
Citations:
PubMed Identifier
32153900
Citation
Wessells KR, Brown KH, Kounnavong S, Barffour MA, Hinnouho GM, Sayasone S, Stephensen CB, Ratsavong K, Larson CP, Arnold CD, Harding KB, Reinhart GA, Lertmemongkolchai G, Fucharoen S, Bernstein RM, Hess SY. Comparison of two forms of daily preventive zinc supplementation versus therapeutic zinc supplementation for diarrhea on young children's physical growth and risk of infection: study design and rationale for a randomized controlled trial. BMC Nutr. 2018 Nov 29;4:39. doi: 10.1186/s40795-018-0247-6. eCollection 2018.
Results Reference
background
PubMed Identifier
29258337
Citation
Hess SY, Hinnouho GM, Barffour MA, Bounheuang B, Arnold CD, Bell D, Marts TH, Kounnavong S. First Field Test of an Innovative, Wider Tape to Measure Mid-Upper Arm Circumference in Young Laotian Children. Food Nutr Bull. 2018 Mar;39(1):28-38. doi: 10.1177/0379572117742502. Epub 2017 Dec 19.
Results Reference
result
PubMed Identifier
29197856
Citation
Hinnouho GM, Barffour MA, Wessells KR, Brown KH, Kounnavong S, Chanhthavong B, Ratsavong K, Kewcharoenwong C, Hess SY. Comparison of haemoglobin assessments by HemoCue and two automated haematology analysers in young Laotian children. J Clin Pathol. 2018 Jun;71(6):532-538. doi: 10.1136/jclinpath-2017-204786. Epub 2017 Dec 2.
Results Reference
result
PubMed Identifier
32048804
Citation
Kingchaiyaphum B, Sanchaisuriya K, Fucharoen G, Chaibunruang A, Hess SY, Hinnouho GM, Barffour MA, Wessells KR, Kounnavong S, Fucharoen S. Hemoglobins F, A2 , and E levels in Laotian children aged 6-23 months with Hb E disorders: Effect of age, sex, and thalassemia types. Int J Lab Hematol. 2020 Jun;42(3):277-283. doi: 10.1111/ijlh.13164. Epub 2020 Feb 12.
Results Reference
result
PubMed Identifier
31889508
Citation
Wessells KR, Hinnouho GM, Barffour MA, Arnold CD, Kounnavong S, Kewcharoenwong C, Lertmemongkolchai G, Schuster GU, Stephensen CB, Hess SY. Impact of Daily Preventive Zinc or Therapeutic Zinc Supplementation for Diarrhea on Plasma Biomarkers of Environmental Enteric Dysfunction among Rural Laotian Children: A Randomized Controlled Trial. Am J Trop Med Hyg. 2020 Feb;102(2):415-426. doi: 10.4269/ajtmh.19-0584.
Results Reference
result
PubMed Identifier
31303184
Citation
Hess SY, Wessells KR, Hinnouho GM, Barffour MA, Sanchaisuriya K, Arnold CD, Brown KH, Larson CP, Fucharoen S, Kounnavong S. Iron status and inherited haemoglobin disorders modify the effects of micronutrient powders on linear growth and morbidity among young Lao children in a double-blind randomised trial. Br J Nutr. 2019 Oct 28;122(8):895-909. doi: 10.1017/S0007114519001715.
Results Reference
result
PubMed Identifier
30591656
Citation
Hinnouho GM, Bernstein RM, Barffour MA, Arnold CD, Wessells KR, Ratsavong K, Bounheuang B, Kounnavong S, Hess SY. Impact of Two Forms of Daily Preventive Zinc or Therapeutic Zinc Supplementation for Diarrhea on Hair Cortisol Concentrations Among Rural Laotian Children: A Randomized Controlled Trial. Nutrients. 2018 Dec 27;11(1):47. doi: 10.3390/nu11010047.
Results Reference
result
PubMed Identifier
30580974
Citation
Barffour MA, Hinnouho GM, Kounnavong S, Wessells KR, Ratsavong K, Bounheuang B, Chanhthavong B, Sitthideth D, Sengnam K, Arnold CD, Brown KH, Hess SY. Effects of Daily Zinc, Daily Multiple Micronutrient Powder, or Therapeutic Zinc Supplementation for Diarrhea Prevention on Physical Growth, Anemia, and Micronutrient Status in Rural Laotian Children: A Randomized Controlled Trial. J Pediatr. 2019 Apr;207:80-89.e2. doi: 10.1016/j.jpeds.2018.11.022. Epub 2018 Dec 21.
Results Reference
result
PubMed Identifier
32356207
Citation
Wessells KR, Brown KH, Arnold CD, Barffour MA, Hinnouho GM, Killilea DW, Kounnavong S, Hess SY. Plasma and Nail Zinc Concentrations, But Not Hair Zinc, Respond Positively to Two Different Forms of Preventive Zinc Supplementation in Young Laotian Children: a Randomized Controlled Trial. Biol Trace Elem Res. 2021 Feb;199(2):442-452. doi: 10.1007/s12011-020-02163-2. Epub 2020 Apr 30.
Results Reference
result
PubMed Identifier
32618258
Citation
Hinnouho GM, Wessells KR, Barffour MA, Sayasone S, Arnold CD, Kounnavong S, Hess SY. Impact of Different Strategies for Delivering Supplemental Zinc on Selected Fecal Markers of Environmental Enteric Dysfunction among Young Laotian Children: A Randomized Controlled Trial. Am J Trop Med Hyg. 2020 Oct;103(4):1416-1426. doi: 10.4269/ajtmh.20-0106.
Results Reference
result
PubMed Identifier
32612816
Citation
Barffour MA, Hinnouho GM, Wessells KR, Kounnavong S, Ratsavong K, Sitthideth D, Bounheuang B, Sengnam K, Chanhthavong B, Arnold CD, Brown KH, Larson CP, Hess SY. Effects of therapeutic zinc supplementation for diarrhea and two preventive zinc supplementation regimens on the incidence and duration of diarrhea and acute respiratory tract infections in rural Laotian children: A randomized controlled trial. J Glob Health. 2020 Jun;10(1):010424. doi: 10.7189/jogh.10.010424.
Results Reference
result
PubMed Identifier
32119742
Citation
Kewcharoenwong C, Schuster GU, Wessells KR, Hinnouho GM, Barffour MA, Kounnavong S, Brown KH, Hess SY, Samer W, Tussakhon I, Peerson JM, Lertmemongkolchai G, Stephensen CB. Daily Preventive Zinc Supplementation Decreases Lymphocyte and Eosinophil Concentrations in Rural Laotian Children from Communities with a High Prevalence of Zinc Deficiency: Results of a Randomized Controlled Trial. J Nutr. 2020 Aug 1;150(8):2204-2213. doi: 10.1093/jn/nxaa037.
Results Reference
result
PubMed Identifier
36167891
Citation
Kewcharoenwong C, Sein MM, Nithichanon A, Khongmee A, Wessells KR, Hinnouho GM, Barffour MA, Kounnavong S, Hess SY, Stephensen CB, Lertmemongkolchai G. Daily preventive zinc supplementation increases the antibody response against pathogenic Escherichia coli in children with zinc insufficiency: a randomised controlled trial. Sci Rep. 2022 Sep 27;12(1):16084. doi: 10.1038/s41598-022-20445-8.
Results Reference
derived
PubMed Identifier
35534778
Citation
Hinnouho GM, Hampel D, Shahab-Ferdows S, Barffour MA, McAnena L, Arnold CD, Ryan Wessells K, Kounnavong S, Allen LH, McNulty H, Hess SY. Daily supplementation of a multiple micronutrient powder improves folate but not thiamine, riboflavin, or vitamin B12 status among young Laotian children: a randomized controlled trial. Eur J Nutr. 2022 Oct;61(7):3423-3435. doi: 10.1007/s00394-022-02890-3. Epub 2022 May 9.
Results Reference
derived

Learn more about this trial

Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation

We'll reach out to this number within 24 hrs